Biotech Values

[DewDiligence]

ENTA’s day-to-day volatility has certainly increased, but I respectfully disagree about the level of interest in the RSV program. Despite the long delays in enrollment of the RSV trials (on account of COVID, indirectly) the ‘RSVP’ readout in 2H22 will be a market-moving event, IMO.